Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

But if you've ever played around with different gluten-free flour mixes, ratios, and recipes, you may have been left with a somewhat soggy-bottomed loaf. There's an easy fix for this, and it's sitting ...

Nov 25 (Reuters) - Cassava Sciences (SAVA.O), opens new tab said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease.

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials ...

What is cassava?  Cassava, also known as manioc or yuca (yep, cassava and yuca are the same things), is a starchy root ...

The Nigerian Senate on Tuesday passed for second reading a bill aimed at promoting the inclusion of cassava in flour and its derivatives, particularly bread. Titled “A Bill for an Act to Provide ...

Cassava Sciences, Inc ... Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that ...

With a background spanning consumer goods giants like Heineken and MasterCard, she brings a unique blend of creativity, strategic thinking, and adaptability to her role as CMO of Cassava Technologies.